

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – February 13, 2019 @ 4:00pm

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. December 12, 2018 DUR Minutes – Vote
- B. December 12, 2018 DUR Recommendations Memorandum
- C. January 9, 2019 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Travers, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Academic Detailing Program Update – See Appendix B

- A. Medication Coverage Activity for January 2019
- B. Pharmacy Helpdesk Activity for January 2019
- C. Academic Detailing Program Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Narrow Therapeutic Index (NTI) Drug List – See Appendix C

- A. Introduction
- B. SoonerCare NTI Drug List

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Arikayce® (Amikacin Liposome Inhalation Suspension) – See Appendix D

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Revcovi™ (Elapegademase-IvIr) – See Appendix E

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Lonhala® Magnair® (Glycopyrrolate Inhalation Solution), Yupelri™ (Revefenacin Inhalation Solution), and Dupixent® (Dupilumab) and to Update the Prior Authorization Criteria for Arnuity® Ellipta® (Fluticasone Furoate), ArmonAir™ RespiClick® (Fluticasone Propionate), AirDuo™ RespiClick® (Fluticasone Propionate/Salmeterol), Breo® Ellipta® (Fluticasone Furoate/Vilanterol), Trelegy™ Ellipta® (Fluticasone Furoate/Umeclidinium/Vilanterol), Xolair® (Omalizumab), and Fasentra™ (Benralizumab) – See Appendix F

- A. Introduction
- B. Market News and Updates

C. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Lokelma™ (Sodium Zirconium Cyclosilicate) and to Update the Veltassa® (Patiromer) Prior Authorization Criteria – See Appendix G

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Tavalisse™ (Fostamatinib), Doptelet® (Avatrombopag), and Mulpleta® (Lusutrombopag) – See Appendix H

- A. Introduction
- B. Market News and Updates
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Connell, Dr. Muchmore, Chairman:

11. Action Item – Vote to Prior Authorize Carbaglu® (Carglumic Acid) – See Appendix I

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

12. Action Item – Vote to Prior Authorize Xelpros™ (Latanoprost 0.005% Emulsion) – See Appendix J

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

13. Action Item – Vote to Prior Authorize Makena® [Hydroxyprogesterone Caproate Subcutaneous (Sub-Q) Auto-Injector] – See Appendix K

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

14. Action Item – Vote to Prior Authorize Akynzeo® IV [Fosnetupitant/Palonosetron Injection for Intravenous (IV) Use] – See Appendix L

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

15. Annual Review of Anticonvulsants and 30-Day Notice to Prior Authorize Epidiolex® (Cannabidiol), Diacomit® (Stiripentol), and Sympazan™ (Clobazam Oral Film) – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of Anticonvulsants
- C. Prior Authorizations of Anticonvulsants
- D. Market News and Updates
- E. Epidiolex® (Cannabidiol Oral Solution) Product Summary
- F. Diacomit® (Stiripentol) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Anticonvulsants

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

16. Annual Review of Anti-Migraine Medications and 30-Day Notice to Prior Authorize Aimovig™ (Erenumab-aooe), Ajovy™ (Fremanezumab-vfrm), and Emgality™ (Galcanezumab-gnlm) – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Migraine Medications
- C. Prior Authorization of Anti-Migraine Medications
- D. Market News and Updates

- E. Aimovig™ (Erenumab-aooe) Product Summary
- F. Ajovy™ (Fremanezumab-vfrm) Product Summary
- G. Emgality™ (Galcanezumab-gnlm) Product Summary
- H. Cost Comparison
- I. College of Pharmacy Recommendations
- J. Utilization Details of Anti-Migraine Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

17. 30-Day Notice to Prior Authorize Gamifant® (Emapalumab-lzsg) – See Appendix O

- A. Introduction
- B. Gamifant® (Emapalumab-lzsg) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Connell, Dr. Muchmore, Chairman:

18. 30-Day Notice to Prior Authorize Firdapse® (Amifampridine) – See Appendix P

- A. Introduction
- B. Market News and Updates
- C. Firdapse® (Amifampridine) Product Summary
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

19. Annual Review of Erythropoietin Stimulating Agents (ESAs) and 30-Day Notice to Prior Authorize Retacrit™ (Epoetin Alfa-epbx) – See Appendix Q

- A. Current Prior Authorization Criteria
- B. Utilization of ESAs
- C. Prior Authorization of ESAs
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of ESAs (Pharmacy Claims)
- G. Utilization Details of ESAs (Medical Claims)

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

20. Annual Review of Parkinson's Disease (PD) Medications and 30-Day Notice to Prior Authorize Inbrija™ (Levodopa Inhalation) and Osmolex ER™ [Amantadine Extended-Release (ER)] – See Appendix R

- A. Current Prior Authorization Criteria
- B. Utilization of PD Medications
- C. Prior Authorization of PD Medications
- D. Market News and Updates
- E. Inbrija™ (Levodopa Inhalation) Product Summary
- F. Osmolex ER™ (Amantadine ER) Product Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of PD Medications

Non-Presentation: Questions Only:

21. Industry News and Updates – See Appendix S

- A. Introduction
- B. News and Updates

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

22. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix T

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

23. Future Business* (Upcoming Product and Class Reviews)

- A. Multiple Sclerosis Medications
- B. Lymphoma Medications
- C. Chronic Lymphocytic Leukemia Medications

D. Hereditary Angioedema Medications

E. Osteoporosis Medications

**Future business subject to change.*

24. Adjournment